Zomedica, Seraph partner on human diagnostic tech for veterinary clinicsMay 14, 2018 Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, has partnered with Seraph Biosciences Inc., a human biomedical device company, to develop and market point-of-care pathogen diagnostic technology for urine and fecal sampling. Leveraging Raman spectroscopy principles, the ZM-020 will feature minimal sample preparation time and deliver fast, in-clinic results and enhanced workflow, according to Zomedica. The instrument will provide real-time, reagentless, and fully automated identification of pathogens and disease indicators, building upon a laser-based spectroscopy technique to identify biological and biochemical signatures in complex biological samples. Marketing and sales are expected to begin in 2019, with an initial focus on canines and expanding into feline applications post-launch. "We believe that ZM-020 will enable us to make a significant improvement to the diagnostic workflow of the veterinary clinic," said Stephanie Morley, DVM, chief operating officer and vice president of product development for Ann Arbor, Mich.-based Zomedica. "If we are successful in our development efforts, we believe that the ability to screen for a wide variety of pathogens with a single diagnostic instrument, beginning with urine and fecal samples, will be a game changer for the modern veterinary clinical team."
SPONSORED CONTENTSwitch to Triple Protection in One Monthly DoseSee the difference of triple protection with the one monthly chew. + Learn More
Zomedica announces therapeutic development milestonesDecember 13, 2017Zomedica Pharmaceuticals Corp. veterinary pharmaceutical and diagnostic company announced a development update on the company's four therapeutic candidates for use in companion animals, namely dogs and cats. ZM-012 and ZM-007: Metronidazole for acute diarrhea in dogs Development milestones for ZM-012 and ZM-007, complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs include: Finalized novel tablet formulation for ZM-012 to replace the large, bitter tasting human-approved generic tablet commonly prescribed by veterinarians for their canine patients. The beef-flavored oral tablets are intended for dogs greater than 9 pounds or 4 kilograms. Finalized the oral suspension formulation for ZM-007, which is intended for small breeds and puppies under 9 pounds or 4 kilograms. Completed pilot testing for both formulations at Michigan State University College of Veterinary Medicine to measure metronidazole's effectiveness to treat acute diarrhea in dogs. Scheduled December 2017 pre-submission meeting with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) to present the regulatory strategy and development plan for ZM-012. A safety study will commence for ZM-012 in the first half of 2018 for completion in the second half of 2018. The company also expects to hold a pre-submission …
